FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3205573658> ?p ?o ?g. }

• W3205573658 endingPage "S41" @default.
• W3205573658 startingPage "S41" @default.
• W3205573658 abstract "BACKGROUND Non invasive cardiac radio-ablation (RA) has emerged as an alternative to escalating anti arrhythmic drugs (AADs) in patients who are unwilling or unable to undergo catheter ablation (CA) for recurrent ventricular tachycardia (VT). We present our initial experience of treating 9 patients on a compassionate use basis and offer insights into programme development and delivery in Canada. METHODS AND RESULTS Twenty four patients have been referred to the programme since August 2019. We have treated 9 patients with RA as 12 patients declined and another three underwent emergent CA for VT storm. Of the 15 patients who did not receive RA, 10 are now deceased (67%). Following RA one patient (11%) deceased at 11 months due to respiratory infection. Although highly selective, clinical characteristics between those receiving and not receiving RA are similar. Patients undergoing RA are medically stabilised and receive echo, CT and PET scanning similar to patients undergoing CA. All 9 patients underwent non invasive EP study (NIPS) under light sedation administered by a single IV cannula without complication. VT is induced using the ICD in situ and mapped using the CardioInsight ECGi system. Targets for RA are identified combining the ECGi data with the contemporaneous imaging data. This analogue process involves Cardiac EP/ Imaging, Radiation Oncologists and Medical Physicists. The median time to RA from NIPS is 12 working days (IQR 8, 20). A single fraction of 25 Gy is targeted using 4D-CT with an average on beam time of 15 minutes. All patients receive Rivaroxaban 20 mg for thirty days post RA. Thus far 1 patient (11%) has suffered pneumonitis requiring a 4 week course of oral corticosteroids, but there have been no other adverse events attributable to RA. Post RA 8 patients (89%) experienced an immediate reduction in VT burden as recorded by their ICD. As compared to the 6 months prior to RA, there was a greater than 90% reduction in VT requiring ICD therapy (ATP or shocks) and at 9 months only 1 patient (11%) has suffered recurrent ICD shocks. The majority of patients (67%) have had antiarrhythmic drug therapy reduced or withdrawn post RA. CONCLUSION Non invasive cardiac radioablation appears safe, well tolerated and effective in the short term for those unwilling or unable to receive catheter ablation for recurrent VT. Several opportunities remain to improve logistics, targeting and availability of the procedure to improve outcomes for this cohort of patients in Canada. Non invasive cardiac radio-ablation (RA) has emerged as an alternative to escalating anti arrhythmic drugs (AADs) in patients who are unwilling or unable to undergo catheter ablation (CA) for recurrent ventricular tachycardia (VT). We present our initial experience of treating 9 patients on a compassionate use basis and offer insights into programme development and delivery in Canada. Twenty four patients have been referred to the programme since August 2019. We have treated 9 patients with RA as 12 patients declined and another three underwent emergent CA for VT storm. Of the 15 patients who did not receive RA, 10 are now deceased (67%). Following RA one patient (11%) deceased at 11 months due to respiratory infection. Although highly selective, clinical characteristics between those receiving and not receiving RA are similar. Patients undergoing RA are medically stabilised and receive echo, CT and PET scanning similar to patients undergoing CA. All 9 patients underwent non invasive EP study (NIPS) under light sedation administered by a single IV cannula without complication. VT is induced using the ICD in situ and mapped using the CardioInsight ECGi system. Targets for RA are identified combining the ECGi data with the contemporaneous imaging data. This analogue process involves Cardiac EP/ Imaging, Radiation Oncologists and Medical Physicists. The median time to RA from NIPS is 12 working days (IQR 8, 20). A single fraction of 25 Gy is targeted using 4D-CT with an average on beam time of 15 minutes. All patients receive Rivaroxaban 20 mg for thirty days post RA. Thus far 1 patient (11%) has suffered pneumonitis requiring a 4 week course of oral corticosteroids, but there have been no other adverse events attributable to RA. Post RA 8 patients (89%) experienced an immediate reduction in VT burden as recorded by their ICD. As compared to the 6 months prior to RA, there was a greater than 90% reduction in VT requiring ICD therapy (ATP or shocks) and at 9 months only 1 patient (11%) has suffered recurrent ICD shocks. The majority of patients (67%) have had antiarrhythmic drug therapy reduced or withdrawn post RA. Non invasive cardiac radioablation appears safe, well tolerated and effective in the short term for those unwilling or unable to receive catheter ablation for recurrent VT. Several opportunities remain to improve logistics, targeting and availability of the procedure to improve outcomes for this cohort of patients in Canada." @default.
• W3205573658 created "2021-10-25" @default.
• W3205573658 creator A5002947500 @default.
• W3205573658 creator A5013947954 @default.
• W3205573658 creator A5027221531 @default.
• W3205573658 creator A5032922990 @default.
• W3205573658 creator A5038013368 @default.
• W3205573658 creator A5044394372 @default.
• W3205573658 creator A5047845715 @default.
• W3205573658 creator A5062337728 @default.
• W3205573658 date "2021-10-01" @default.
• W3205573658 modified "2023-09-25" @default.
• W3205573658 title "NON-INVASIVE CARDIAC RADIOABLATION FOR RECURRENT VENTRICULAR TACHYCARDIA: INITIAL RESULTS AND INSIGHTS" @default.
• W3205573658 doi "https://doi.org/10.1016/j.cjca.2021.07.087" @default.
• W3205573658 hasPublicationYear "2021" @default.
• W3205573658 type Work @default.
• W3205573658 sameAs 3205573658 @default.
• W3205573658 citedByCount "0" @default.
• W3205573658 crossrefType "journal-article" @default.
• W3205573658 hasAuthorship W3205573658A5002947500 @default.
• W3205573658 hasAuthorship W3205573658A5013947954 @default.
• W3205573658 hasAuthorship W3205573658A5027221531 @default.
• W3205573658 hasAuthorship W3205573658A5032922990 @default.
• W3205573658 hasAuthorship W3205573658A5038013368 @default.
• W3205573658 hasAuthorship W3205573658A5044394372 @default.
• W3205573658 hasAuthorship W3205573658A5047845715 @default.
• W3205573658 hasAuthorship W3205573658A5062337728 @default.
• W3205573658 hasConcept C126322002 @default.
• W3205573658 hasConcept C126838900 @default.
• W3205573658 hasConcept C164705383 @default.
• W3205573658 hasConcept C2776131983 @default.
• W3205573658 hasConcept C2776331378 @default.
• W3205573658 hasConcept C2778198053 @default.
• W3205573658 hasConcept C2778902805 @default.
• W3205573658 hasConcept C2910474132 @default.
• W3205573658 hasConcept C71924100 @default.
• W3205573658 hasConcept C78085059 @default.
• W3205573658 hasConceptScore W3205573658C126322002 @default.
• W3205573658 hasConceptScore W3205573658C126838900 @default.
• W3205573658 hasConceptScore W3205573658C164705383 @default.
• W3205573658 hasConceptScore W3205573658C2776131983 @default.
• W3205573658 hasConceptScore W3205573658C2776331378 @default.
• W3205573658 hasConceptScore W3205573658C2778198053 @default.
• W3205573658 hasConceptScore W3205573658C2778902805 @default.
• W3205573658 hasConceptScore W3205573658C2910474132 @default.
• W3205573658 hasConceptScore W3205573658C71924100 @default.
• W3205573658 hasConceptScore W3205573658C78085059 @default.
• W3205573658 hasIssue "10" @default.
• W3205573658 hasLocation W32055736581 @default.
• W3205573658 hasOpenAccess W3205573658 @default.
• W3205573658 hasPrimaryLocation W32055736581 @default.
• W3205573658 hasRelatedWork W1483882493 @default.
• W3205573658 hasRelatedWork W2179224909 @default.
• W3205573658 hasRelatedWork W2607902594 @default.
• W3205573658 hasRelatedWork W2917784727 @default.
• W3205573658 hasRelatedWork W2979757746 @default.
• W3205573658 hasRelatedWork W3036356416 @default.
• W3205573658 hasRelatedWork W3140475451 @default.
• W3205573658 hasRelatedWork W3185665820 @default.
• W3205573658 hasRelatedWork W4225370736 @default.
• W3205573658 hasRelatedWork W4292689102 @default.
• W3205573658 hasVolume "37" @default.
• W3205573658 isParatext "false" @default.
• W3205573658 isRetracted "false" @default.
• W3205573658 magId "3205573658" @default.
• W3205573658 workType "article" @default.